![Emmanuel Huynh](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Emmanuel Huynh
Président chez
ABIONYX PHARMA SA
Profil
Emmanuel Huynh is the founder of H4 Orphan Pharma SAS, founded in 2016, holding the title of Chairman since 2024.
Dr. Huynh is also the founder of Newcap SASU,Newcap SAS..
Dr. Huynh is Chairman at ABIONYX Pharma SA since 2019.
Dr. Huynh is Chairman at Domundi SC.
Dr. Huynh is Director & Vice President at Alfred Fournier Institute.
Dr. Huynh was Chairman at EGEIRO Pharma from 2024 to 2025.
Dr. Huynh earned an MBA from Sciences Po and a doctorate from Sorbonne Université.
Postes actifs de Emmanuel Huynh
| Sociétés | Poste | Début |
|---|---|---|
| ABIONYX PHARMA SA | Président | 12/09/2019 |
Newcap SASU
 Newcap SASU Miscellaneous Commercial ServicesCommercial Services Provides investor relations and strategic communication consulting services | Directeur Général | - |
Domundi SC | Président | - |
Alfred Fournier Institute
 Alfred Fournier Institute Medical/Nursing ServicesHealth Services Operates medical center | Directeur/Membre du Conseil | - |
Newcap SAS
 Newcap SAS Financial ConglomeratesFinance Provides investment services | Fondateur | - |
H4 Orphan Pharma SAS
 H4 Orphan Pharma SAS Pharmaceuticals: MajorHealth Technology Develops biopharmaceutical products for pulmonary diseases | Fondateur | 01/01/2016 |
Anciens postes connus de Emmanuel Huynh
| Sociétés | Poste | Fin |
|---|---|---|
| THERAVET SA | Président | 27/01/2025 |
Formation de Emmanuel Huynh
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
12
Relations au 1er degré
9
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 9 |
|---|---|
ABIONYX Pharma SA
 ABIONYX Pharma SA Pharmaceuticals: MajorHealth Technology Discovers, develops and commercializes novel HDL therapies for the treatment of cardiovascular and metabolic diseases | Health Technology |
Sciences Po
 Sciences Po Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Sorbonne Université
 Sorbonne Université Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Newcap SASU
Newcap SASU Miscellaneous Commercial ServicesCommercial Services Provides investor relations and strategic communication consulting services | Commercial Services |
Alfred Fournier Institute
Alfred Fournier Institute Medical/Nursing ServicesHealth Services Operates medical center | Health Services |
TheraVet SA
 TheraVet SA Miscellaneous Commercial ServicesCommercial Services Develops new treatments and drugs for animals suffering from osteoarticular diseases | Commercial Services |
Newcap SAS
Newcap SAS Financial ConglomeratesFinance Provides investment services | Finance |
H4 Orphan Pharma SAS
H4 Orphan Pharma SAS Pharmaceuticals: MajorHealth Technology Develops biopharmaceutical products for pulmonary diseases | Health Technology |
Domundi SC |
Choisissez Zonebourse 
